Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Duncan Richards

Today, we formally welcome Professor Duncan Richards as the new Director to OCTRU, replacing Professor Sarah (Sallie) Lamb who, together with Professor Doug Altman founded the CTU back in 2012. 

Professor Richards, an Oxford-trained clinician, joins OCTRU from his previous roles as Head of Clinical Pharmacology and Experimental Medicine at GSK, and Research Director of GSK’s phase 1 and experimental medicine unit in Cambridge (CUC).

Professor Lamb is moving to a new role at Exeter University, but will continue as Strategic Lead for OCTRU’s Rehabilitation Research group. 

Members of the unit are looking forward to the continued evolution of OCTRU under Professor Richards, building on its reputation as a firmly established CTU conducting numerous clinical trials across all phases and areas of medicine. Professor Richards said: ‘In my short time in Oxford I have been tremendously impressed by the breadth and quality of work undertaken by OCTRU and its partners. I would like to pay tribute Sallie and the team for building a robust but flexible organisation that is ready to take on new challenges and opportunities as the clinical trials portfolio continues to evolve.’

Similar stories

SCIENCE spreads across the world

Oxford Trauma are pleased to open their first overseas site for the SCIENCE study.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.

PRoCuRe opens to recruitment

The Partial Rotator Cuff Tear Repair Trial (PRoCuRe) is open to recruitment at Oxford University Hospitals NHS Foundation Trust after achieving OCTRU Green Light approval!

IMP-MEL Trial given Green Light to open

OCTRU have now given Green Light approval for IMP MEL to open. This is a phase 1 first-in-human dose finding/randomised phase 2 study of IMM60 and pembrolizumab in advanced melanoma and NSCLC.

WISE opens to recruitment

The WISE Study - Wrist Injury Strengthening Exercise: a randomised multicentre feasibility study of resistance exercise versus usual care for optimising function after distal radius fracture in adults aged 50 years or over has now received OCTRU Green Light approval and has opened to recruitment.